Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy

2021 ◽  
Author(s):  
Matthew Ramotar ◽  
Melvin L.K. Chua ◽  
Hong Truong ◽  
Ali Hosni ◽  
Melania Pintilie ◽  
...  
Keyword(s):  
Treatment Individualization

Individualizing and Combining Treatments in Autism Spectrum Disorder

2017 ◽  
Vol 26 (2) ◽  
pp. 114-119 ◽  
Author(s):  
Giacomo Vivanti
Keyword(s):  
Autism Spectrum Disorder ◽  
Early Intervention ◽  
Treatment Response ◽  
Research Agenda ◽  
Children With Autism ◽  
Autism Spectrum ◽  
Intervention Programs ◽  
Rational Approach ◽  
Autism Treatment ◽  
Treatment Individualization

Although several early intervention programs can be efficacious in improving outcomes of children with autism, treatment response is variable, leading most families to enroll their child in several interventions simultaneously. Because knowledge on the effects of combining different therapies is limited, it is critically important to develop and test predictions on how the “active ingredients” of different interventions interact with child characteristics and with one another when combined. An obstacle to this research agenda is the “pre-paradigmatic” stage of the autism early intervention field, in which many practices are organized around seemingly irreconcilable vocabularies. I argue that a formalization of the explanatory structures informing different treatments—based on the four parameters of logical coherence, falsifiability, parsimony, and consilience—can provide a conceptual lingua franca for the formulation of testable hypotheses on treatment individualization and combination, thus facilitating a more coherent and rational approach to research in this area.

scholarly journals Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study

PLoS ONE ◽  
2015 ◽  
Vol 10 (7) ◽  
pp. e0134839 ◽  
Author(s):  
Wolf Peter Hofmann ◽  
Stefan Mauss ◽  
Thomas Lutz ◽  
Andreas Schober ◽  
Klaus Böker ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Cohort Study ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Peginterferon Alfa ◽  
Treatment Individualization

scholarly journals Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

2011 ◽  
Vol 29 (9) ◽  
pp. 1140-1145 ◽  
Author(s):  
Athanassios Argiris ◽  
Michalis V. Karamouzis ◽  
William E. Gooding ◽  
Barton F. Branstetter ◽  
Shilong Zhong ◽  
...  
Keyword(s):  
Head And Neck ◽  
Methylenetetrahydrofolate Reductase ◽  
Response Rate ◽  
Complete Response ◽  
Nucleotide Polymorphisms ◽  
Bleeding Events ◽  
History Of ◽  
Grade 3 ◽  
Endothelial Growth Factor ◽  
Treatment Individualization

Purpose We hypothesized that bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), will potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell carcinoma of the head and neck (SCCHN). Patients and Methods Patients with previously untreated, recurrent, or metastatic SCCHN were treated with pemetrexed 500 mg/m2 and bevacizumab 15 mg/kg given intravenously every 21 days with folic acid and B12 supplementation until disease progression. Primary end point was time-to-progression (TTP). DNA was isolated from whole blood samples for the detection of polymorphisms in thymidylate synthase, methylenetetrahydrofolate reductase (MTHFR), and VEGF. Results Forty patients were enrolled. The median TTP was 5 months, and the median overall survival (OS) was 11.3 months. In 37 evaluable patients, the overall response rate was 30%, including a complete response rate of 5%, and the disease control rate was 86%. Grade 3 to 5 bleeding events occurred in six patients (15%): four were grade 3, and two were fatal. Other serious toxicities in 10% or more of patients included neutropenia (10%) and infection (12.5%). One patient died of sepsis after receiving eight cycles of therapy. For the MTHFR A1298C (rs1801131) single nucleotide polymorphisms, homozygote patients with AA had worse OS (P = .034). Conclusion The addition of bevacizumab to pemetrexed resulted in promising efficacy outcomes in SCCHN. Bleeding events were frequent but some may have been due to natural history of disease. Polymorphisms in MTHFR may offer potential for treatment individualization.

scholarly journals Periodontal Tissues State and Psychophysiological Addiction: the Effectiveness of Treatment and Rehabilitation Complexes in Patients with Maxillofacial Area Injuries and Diseases

2016 ◽  
Vol 23 (3) ◽  
Author(s):  
A O Hryhorova
Keyword(s):  
Effective Treatment ◽  
Inflammatory Diseases ◽  
Clinical Monitoring ◽  
Complex Treatment ◽  
Treatment Need ◽  
Extended Treatment ◽  
Periodontal Tissues ◽  
Psychophysiological State ◽  
Treatment Individualization

The results of the clinical monitoring of patients with injuries and inflammatory diseases of maxillofacial area proved that the presence of nicotine psychophysiological addiction is a significant factor for the effective treatment of patients with maxillofacial area injuries, and in the case of extended treatment and rehabilitation complex greater efficiency is possible due to the reduction of periodontium treatment need by 27.6% in post-mobilization period. In patients with nicotine physiological addiction on the background of inflammatory diseases, in case of its use it is possible to achieve greater efficiency due to the reduction of the periodontium treatment need by 21.8%. Thus, diagnostics and consideration of the type of psychophysiological addiction can be considered as additional criteria of complex treatment individualization taking into account the psychophysiological state of patients in the course of prescribed treatment and rehabilitation complex application.

scholarly journals ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES Study

2022 ◽  
Vol 8 ◽  
Author(s):  
Manuela Monti ◽  
Tom Degenhardt ◽  
Etienne Brain ◽  
Rachel Wuerstlein ◽  
Alessandra Argusti ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
National Level ◽  
Academic Research ◽  
Competent Authority ◽  
New Drugs ◽  
Medical Needs ◽  
Cancer Experience ◽  
Personalized Cancer ◽  
Treatment Individualization

Background: Academic research is important to face unmet medical needs. The Oncological community encounters many hurdles in setting up multicenter investigator-driven trials mainly due to administrative complexity. The purpose of a network organization at a multinational level is to facilitate clinical trials through standardization, coordination, and education for drug development and regulatory approval.Methods: The application of an European grant foresees the creation of a consortium which aims at facilitating multi-center academic clinical trials.Results: The ERA-NET TRANSCAN Call 2011 on “Validation of biomarkers for personalized cancer medicine” was released on December 2011. This project included Italian, Spanish, French and German centers. The approval process included Consortium constitution, project submission, Clinical Trial Submission, and activation on a national level. The different timescales for submitting study documents in each Country and the misalignment of objections by each Competent Authority CA, generated several requests for changes to the study documents which meant amendments had to be made; as requested by the 2001/20/EC Directive, the alignment of core documents is mandatory. This procedure impacted significantly on study activation timelines. Time to first patient in was 14, 10, 28, and 31 months from the date of submission in Italy, France, Spain, and Germany, respectively. Accrual was stopped on 22nd January 2021 due to an 18F FES shortage as the primary reason but also for having exceeded the project deadlines with consequent exhaustion of the funds allocated for the project.Conclusions: Pharmaceutical companies might be reluctant to fund research projects aimed at treatment individualization if the approval for a wider indication has already been achieved. Academic trials therefore become fundamental for promoting trials which are not attractive to big pharma. It was very difficult and time consuming to activate an academic clinical trial, for this reason, a study may become “old” as new drugs entered into the market. National institutions should promote the development of clinical research infrastructures and network with competence in regulatory, ethical, and legal skills to speed up academic research.

scholarly journals An Innovative High-Tech Acupuncture Product: SXDZ-100 Nerve Muscle Stimulator, Its Theoretical Basis, Design, and Application

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Xinyan Gao ◽  
Peijing Rong ◽  
Liang Li ◽  
Wei He ◽  
Hui Ben ◽  
...  
Keyword(s):  
Theoretical Basis ◽  
Animal Experiments ◽  
High Tech ◽  
Manual Acupuncture ◽  
High Tech Product ◽  
Receptor Adaptation ◽  
Wdr Neurons ◽  
Nerve Muscle ◽  
Treatment Individualization ◽  
Design And Application

We introduce the theoretical basis, design, and application of a patented innovative high-tech product, SXDZ-100 nerve and muscle stimulator. This product is featured with a built-in chip containing transcoding information from different acupuncture manipulation collected from the wide dynamic neurons (WDR) in the spinal dorsal horn in animal experiments, which is bioinformation feedback therapy. The discharges of WDR neurons excited by different manipulations are analyzed using chaos theory in this study. It combines the advantages of manual acupuncture (MA) like no receptor adaptation and treatment individualization and that of electroacupuncture (EA) such as relatively low stimulation intensity and good quantification and thus makes it more effective than common stimulators in acupuncture clinic.

Sign in / Sign up

Export Citation Format

Share Document